Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
indepth-I can assure you I will stay around and with a big store of saved posts.
Where did you find that #?
I agree red, put a new pic up and the pps will go up,lol.
Wow, did I get excited when I pulled up my TDA account and saw NNVC at .92 on main accounts screen. Then to bust my balloon when I clicked on NNVC and it was .39.
The .92 is still there for some reason.
MFIC Corporation Appoints Michael C. Ferrara Chief Executive Officer
9:03a ET November 14, 2007 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today announced that Michael C. Ferrara has been appointed Chief Executive Officer and a member of the Company's Board of Directors. Mr. Ferrara was most recently President and CEO of X-Rite where he led the corporation's reemergence as the global leader of its industry. X-Rite, a $352 million market capitalization NASDAQ-traded company (XRIT), is the global leader in color science and technology, developing, manufacturing and marketing innovative color management solutions for industrial, commercial and retail applications. Under Mr. Ferrara's leadership, X-Rite grew organically to achieve record-level revenues and earnings through the introduction of 61 new products in five years, distribution gains and industry-changing merger and acquisitions in the color technology space-including the acquisition of Amazys Holding AG, which was awarded in 2006 "The International Deal of the Year" by The M&A Advisor(TM). Mr. Ferrara also has extensive experience in building marketing and distribution channels with strategic partners in markets throughout the world, including Asia-Pacific and EMEA--areas of considerable focus for MFIC moving forward.
"Mike's relationships on Wall Street, his strategic vision and his proven ability to lead companies to success will be important in unlocking the value of MFIC as we continue to position the Company for long-term sustainable growth," said James N. Little, Ph.D., Acting Chairman of the Board of Directors. "The Board believes Mike's experience is an excellent fit for the breadth of opportunity at MFIC and we look forward to working with him to facilitate MFIC's growth and success under his leadership."
"MFIC has put in place a foundation to support the growth-potential of the Company," said Michael C. Ferrara, Chief Executive Officer. "I look forward to working with the team around the world to capitalize on our innovative technologies and products such that the potential of MFIC is realized for all stakeholders and shareholder value is consistently improved."
Michael Ferrara was previously Chief Executive Officer and President of X-Rite Incorporated. Prior to X-Rite, Mr. Ferrara was CEO of Marine Optical Group, CEO of N.I. World Trade, a trading subsidiary of National Intergroup (formerly National Steel) and held positions of increasing seniority over an 18-year period at Westinghouse Electric Corporation. Mr. Ferrara has a B.S in electrical engineering from Villanova University and completed the Program for Management Development (PMD) at Harvard Business School
MFIC Corporation Announces Third Quarter Financial Results
4:35p ET November 13, 2007 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today reported financial results for the quarter ended September 30, 2007. MFIC is an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.
MFIC reported that for the third quarter ended September 30, 2007, the Company posted revenues of approximately $2.3 million compared to $3.6 million during the third quarter of 2006, representing a decrease of approximately 36%. Third quarter sales were impacted by decreases in all geographic markets.
In North America, lower sales were primarily driven by (i) a customer's decision to request additional enhancements to a major system order that delayed delivery and revenue recognition until a later date; and (ii) an expected decrease in spare part sales as a result of a previously disclosed decision by a major customer to reschedule delivery due to a change in their production schedule.
Lower foreign sales were driven primarily by a decrease in the sale of machines to significant customers, particularly in Asia. This includes a continued decrease in sales made by MFIC's Japanese distributor. The distributor has not been aggressively selling MFIC products due to its technical issue with a major installation. MFIC believes the recurring problems with these machines are the direct result of the maintenance of the machines by the distributor and the customer. MFIC has assigned a dedicated technical team which has worked very closely with the distributor's service group and the distributor's service group has since taken steps to address the issues. In addition, Robert P. Bruno, President and Chief Operating Officer of MFIC, traveled to Japan in September to meet with the distributor's management team. MFIC continues to work on this important issue.
"We are certainly disappointed with our third-quarter results," said Robert P. Bruno, President and Chief Operating Officer of MFIC Corporation. "However, while our sales in Japan continue to fall short of previous quarters, we believe we have a good foundation in Asia, specifically in China and Korea where we are encouraged by the demand we have seen in these markets over time. We are also pleased with the initial sales response to the M-110P, introduced in late September of 2007. We have received orders for the first seven production units and have issued numerous additional quotations. We expect to begin delivering units late this year or in early 2008. In addition, we continue to see strong sales of our biopharmaceutical production machines to some of our largest customers."
"While this has been a difficult quarter for MFIC, the Company is financially sound, having cash and receivables that are well in excess of current liabilities," said James N. Little, Ph.D., Acting Chairman of MFIC Corporation. "These lumpy quarters, while taken very seriously, are normal in the capital goods business. We continue to focus on building long-term sustainable growth and our backlog has grown substantially since the quarter's end."
For the third quarter ended September 30, 2007, the Company posted a net loss of $859,000, or $.08 per diluted share, as compared with net income of $85,000, or $0.01 per diluted share, for the quarter ended September 30, 2006. The third quarter 2007 results included no income tax provision while the third quarter of 2006 included an income tax expense of $57,000.
Operating expenses increased by $200,000, or 10.5% to $2.1 million for the quarter ended September 30, 2007 from $1.9 million for the quarter ended September 30, 2006. The increase was primarily due to increases in sales and marketing expenses, administrative costs associated with the departure of the Company's prior CEO and costs associated to fill the vacancy and a planned increase in public relations.
The Company's order backlog at September 30, 2007 was $3.8 million compared to backlogs of $4.9 million and $3.0 million on September 30, 2006 and June 30, 2007, respectively. Backlog grew to approximately $4.9 million as of November 9, 2007, including a letter of intent to purchase a significant production system from a major pharmaceutical customer. Backlog represents orders in hand that typically take between one and six months to deliver, with the exception of a spare parts supply order scheduled to ship over a longer period.
For the nine-month period ended September 30, 2007, revenues decreased by $1.9 million or 18.0%, to $8.7 million, and the Company reported a net loss of $0.14 per diluted share, as compared with $10.6 million in revenues, and a net profit of $0.02 per diluted share, for the first nine months of 2006.
During the third quarter 2007 MFIC Corporation accomplished significant milestones:
-- Launched the M-110P Microfluidizer(R) processor, an innovative benchtop "Plug and Play" machine that provides a solution for customers lacking compressed air required to operate MFIC's existing air operated laboratory equipment
-- Announced that the Company's subsidiary, Microfluidics, was named a technology category winner in the third annual Nanotech Briefs(R) Nano 50(TM) Awards for its revolutionary new Microfluidics Reaction Technology (MRT)_a next-generation approach in the production of nanosuspensions to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs
-- Continued to make solid progress in the search for a CEO candidate
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three For The Nine Months Ended Months Ended September 30, September 30, ----------------------------------- 2007 2006 2007 2006 -------- -------- -------- -------- Revenues $ 2,311 $ 3,553 $ 8,670 $10,614 Cost of sales 1,118 1,558 3,765 4,806 -------- -------- -------- -------- Gross profit 1,193 1,995 4,905 5,808 -------- -------- -------- -------- Operating expenses: Research and development 436 424 1,411 1,274 Selling 840 723 2,649 2,081 General and administrative 784 707 2,267 2,030 -------- -------- -------- -------- 2,060 1,854 6,327 5,385 -------- -------- -------- -------- (Loss) income from operations (867) 141 (1,422) 423 Interest expense (7) (9) (15) (29) Interest income 15 10 53 31 -------- -------- -------- -------- (Loss) income before income tax provision (859) 142 (1,384) 425 Income tax provision - 57 - 170 -------- -------- -------- -------- Net (loss) income $ (859) $ 85 $(1,384) $ 255 ======== ======== ======== ======== Net (loss) income per common share: Basic $ (0.08) $ 0.01 $ (0.14) $ 0.03 Diluted $ (0.08) $ 0.01 $ (0.14) $ 0.02 Weighted average number of common and common equivalent shares outstanding: Basic 10,203 10,045 10,169 9,991 Diluted 10,203 10,561 10,169 10,517
Summary Consolidated Unaudited Balance Sheet Information (Unaudited - in thousands) ---------------------------------------------------------------------- September December 30, 31, 2007 2006 --------------------------------------------------- --------- -------- Current Assets(a) $6,361 $7,857 --------------------------------------------------- --------- -------- Current Liabilities $1,931 $2,213 --------------------------------------------------- --------- -------- Total Stockholders' Equity $4,831 $5,948 --------------------------------------------------- --------- -------- (a)Cash on hand at September 30, 2007 is $1.168 million.
SOURCE: MFIC Corporation
MFIC Corporation Jack M. Swig, 617-969-5452 info@mfics.com or MacDougall Biomedical Communications Sarah Cavanaugh, 508-647-0209 scavanaugh@macbiocom.com
Are you talking about the one promised last November or the one due two years ago?
ps. I am saving your post for a reminder later as other interested parties may ask for it.
I've already taken some action-I asked Interpol to investigate but have not received a reply.
Beware of gold email spam/scammers:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24519960
HPGI Gold spam/scam:
Gold Resource Newsletter
Investors move into gold to protect investments as US Dollar spirals.
Hemisphere Gold (HPGI) $1.00
Gold prices are soaring as investors are seeking safe havens from the
spiraling US Dollar. With gold prices up over $200 to $812/ounce
demands
for gold are increasing.
A gold rush is now in effect in Suriname as large deposits having been
discovered and the rush to mine them is at full speed.
Hemisphere Gold has found gold showing as much as 3.55 ounces/ton on
there property which sits right in the middle of the Gold Belt and the
largest mines in the region.
5 Key Points To Consider
1. Gold is Gold, and the prices have been climbing at amazing rates
since January of this year.
2. Demand for Gold supplies is at a n all time high. Analysts believe
these demands and not only holding but increasing in many areas.
3. Hemisphere's cutting edge technology allows them to maximizing its
ability to find gold deposits while there management skills are keeping
costs under control.
4. For investors interested in a Gold Belt Strategy, HPGI is a prime
target as there claim sits right in the middle of several large
producing mines.
5. Hemisphere chief geologist has worked with the largest gold
companies
in Suriname including Newmont and IAMGOLD. These relationships will
prove useful during a large gold strike.
Hemisphere is certainly the next hot stock in the booming gold market.
Media campaigns are set to launch next week and recent news releases
are
already forcing share prices up over 120% in just the last few weeks.
This is the time to carefully consider HPGI as your next investment
opportunity.
PBLS (.003) Phoenix Releases Letter to Shareholders
Tuesday, November 13 2007 11:47 AM, EST Market Wire "US Press Releases "
MADISONVILLE, LA -- (MARKET WIRE) -- 11/13/07 -- Phoenix Associates Land Syndicate ( Phoenix ) (PINKSHEETS: PBLS) releases the following letter to shareholders prepared by its CEO and President, Paul Alonzo.
To Our Shareholders:
Many of our shareholders are asking, "What's going on?" I will answer this question on more of a personal level than a professional level. We did release the Q3-2007 financials prepared by our staff and in that release we provided some information.
We have been personally attacked with some of the most highly inappropriate and slanderous comments that anybody could possibly dream up and all of it is false.
This weekend Carolyn and I attended church, as we do every Sunday, and we met and shook hands with one of the greatest disciples of the Father and the Son that I have ever known and on the other side of the same hall we were confronted by a person whose hand I refused to shake. It occurred to me that this is the kind of decision you as shareholders have to make. I hope the information that follows will assist your decision as a continuing shareholder in Phoenix .
Phoenix was recently damaged by three men that were key administrators with Phoenix and by two women that worked in our Financial Department . One of the women has already admitted to her part, one of the women is being sought by authorities for questioning, one man was fired and two of the men are being sought by police and are fugitives.
Carolyn Alonzo is the CFO of Phoenix and she is not going to be replaced. She is the best that we have and she is the go to person if you want anything done at Phoenix .
Ron Blackburn is our COO and he will not be replaced. He is the one guy that I can count on to get things done.
Phoenix will be trading, selling off, and otherwise eliminating companies that do not make a profit. Phoenix will be a much stronger and improved company when this process is complete.
We do not intend to increase our "Authorized Shares" of common stock or preferred stock above the current levels, and we have no plans to do any kind of reverse split. And further, we do plan to reduce our outstanding shares of common stock. We will be implementing a long-term effort to buy back stock in the open market as earnings and cash flow permit.
As to any of the accumulated dividends that may not as yet been paid to holders of our preferred stock, it is our plan to bring these dividend payments current over the next sixty days or so, as our restructuring program progresses.
The litigation is proceeding with the gravel pit as previously discussed. Phoenix plans little or no revenue from the pit and does not currently report the mine as an asset.
Phoenix continues to work with lenders to expand its interests for the future.
Your investment in Phoenix stock to enhance yourself personally is still the same good bet as it always was -- in my opinion.
Carolyn, Ron and I have invested millions of dollars into Phoenix and we are not going anywhere. Phoenix has had a little blip on the radar screen, but all of the panic is totally unjustified and all of those ridiculous and foolish statements on the Internet are totally without merit.
The key asset of Phoenix is its talented and loyal people. This asset brought Phoenix from a $100,000 per year company to a multi-dimensional, multi-million-dollar-a-year company and this asset will guarantee its future success.
Phoenix will remain a non-reporting pink sheet company in the short term and we will continue to give you more pertinent information in the future than almost any other non-reporting company. I hope you will stay with us as shareholders because Phoenix will remain an interesting and viable company to invest in. I hope this helps your decision.
Paul Alonzo
President and Chief Executive Officer
Phoenix Associates Land Syndicate
About Phoenix Associates
Phoenix Associates Land Syndicate is a holding company with assets in aviation, sand & gravel, soil products, land development, oil and natural gas, commodity brokering, plumbing, trucking, contract hauling, construction, swimming pool construction and construction related industries. For more information go to: www.pbls.biz
Forward-Looking Statements
This press release contains statements that are "forward looking" and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Generally, the words "expect," "intend," "estimate," "will" and similar expressions identify forward-looking statements. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements, or that of our industry, to differ materially from those expressed or implied in any of our forward-looking statements. Statements in this press release regarding the Company's business or proposed business, which are not historical facts, are "forward-looking" statements that involve risks and uncertainties, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.
For More Information Contact:
Mike Mulshine
Osprey Partners
(732) 292-0982
osprey57@optonline.net
That could'nt lower the pps much more :)
Also please forward those deceptive posts to address below.
Wow Maly, this PR is about as astounding as the one you put out a couple of weeks ago telling us your drilling depth had reached XXX feet!
This post pretty well sums up the seconding coming of Stalin (Putin) in Russia:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24492395
Nah blackjack,thanks anyway, I will just wait for either that .14 or.19 you promised everyone 2-3 months ago.
red, have RCMP asked you any questions yet? TIA.
Unigene Announces Financial Results for the Third Quarter of 2007
6:00a ET November 12, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the three months and nine months ended September 30, 2007.
Revenue for the three months ended September 30, 2007 increased to $6,343,000 compared with $1,701,000 for the three months ended September 30, 2006. Revenue for the nine months ended September 30, 2007 increased to $17,390,000 compared with $2,644,000 for the nine months ended September 30, 2006. Revenue from Fortical sales and royalties was $5,771,000 and $13,607,000, respectively, for the three months and nine months ended September 30, 2007.
Fortical royalties were $1,628,000 and $673,000 for the three months ended September 30, 2007 and 2006, respectively, and $4,549,000 and $1,218,000 for the nine months ended September 30, 2007 and 2006, respectively. Fortical sales were $4,143,000 and $9,058,000 for the three months and nine months ended September 30, 2007, respectively. Fortical sales were $837,000 for the three months and nine months ended September 30, 2006. Sales of peptide to Novartis were $2,200,000 for the nine months ended September 30, 2007.
Net loss for the three months ended September 30, 2007 was $240,000, or $0.00 per share, compared with a net loss of $2,515,000, or $0.03 per share, for the three months ended September 30, 2006.
Net loss for the nine months ended September 30, 2007 was $1,778,000, or $0.02 per share, compared with a net loss of $8,759,000, or $0.10 per share, for the nine months ended September 30, 2006.
Operating expenses were $6,304,000 for the three months ended September 30, 2007, compared with $3,897,000 for the three months ended September 30, 2006 and were $18,266,000 for the nine months ended September 30, 2007, compared with $10,440,000 for the nine months ended September 30, 2006. The increases were primarily due to cost of goods sold resulting from the increased product sales to Upsher-Smith and Novartis. The three months ended September 30, 2007 and 2006 includes $84,000 and $134,000, respectively, in expenses for non-cash stock option compensation. The nine months ended September 30, 2007 and 2006 includes $766,000 and $561,000, respectively, in expenses for non-cash stock option compensation.
The Company's cash balance at September 30, 2007 was $7,004,000, an increase of approximately $3,647,000 from December 31, 2006. Accounts receivable at September 30, 2007 were $3,416,000, an increase of $2,176,000 from December 31, 2006.
Deferred licensing fees increased $4,641,000 from December 31, 2006, primarily due to the $5,500,000 Phase III milestone payment received from Novartis which was only partially recognized as revenue in the first nine months of 2007.
The Company believes that cash on hand, as well as cash generated from Fortical sales and royalties, will be sufficient to meet its obligations for the next twelve months.
Following are financial highlights:
-- Third quarter revenues increased 34% from second quarter
-- Third quarter Fortical sales and royalties increased 71% from second quarter
-- Fortical's market share improved to 49%
-- Positive operating income for third quarter
-- Positive cash flow from operations for nine months
"We are encouraged by the significant improvements in our financial performance," commented Dr. Warren Levy, President and CEO of Unigene. "With a stronger balance sheet and cash position, we intend to proceed with additional clinical studies for some of our peptides, as well as pre-clinical and clinical studies in our Site Directed Bone Growth Program."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
UNIGENE LABORATORIES, INC. CONDENSED BALANCE SHEETS September 30, December 31, 2007 2006 -------------- -------------- ASSETS (Unaudited) ---------------------------------------- Current assets: Cash and cash equivalents $ 7,004,197 $ 3,357,351 Accounts receivable 3,415,961 1,240,114 Inventory 2,676,225 5,283,000 Prepaid expenses and other current assets 226,530 303,444 -------------- -------------- Total current assets 13,322,913 10,183,909 Noncurrent inventory 445,958 -- Property, plant and equipment, net 2,419,560 2,364,141 Investment in joint venture 29,295 30,545 Patents and other intangibles, net 1,734,509 1,438,848 Other assets 133,933 33,879 -------------- -------------- Total assets $ 18,086,168 $ 14,051,322 ============== ============== LIABILITIES AND STOCKHOLDERS' DEFICIT ---------------------------------------- Current liabilities: Accounts payable $ 906,455 $ 884,958 Accrued expenses - other 2,093,011 1,806,707 Current portion - deferred licensing fees 1,262,756 762,752 Notes payable - stockholders -- 8,105,000 Accrued interest - stockholders -- 8,081,180 Current portion - capital lease obligations 49,029 70,780 Income tax payable 83,000 -- -------------- -------------- Total current liabilities 4,394,251 19,711,377 Notes payable-stockholders 15,737,517 -- Accrued interest-stockholders 473,218 -- Deferred licensing fees, excluding current portion 12,297,022 8,156,262 Capital lease obligations, excluding current portion 8,223 40,880 Deferred compensation 365,682 330,643 -------------- -------------- Total liabilities 33,275,913 28,239,162 -------------- -------------- Commitments and contingencies Stockholders' deficit: Common Stock - par value $.01 per share, authorized 135,000,000 shares, issued and outstanding: 87,750,715 shares in 2007 and 87,731,015 shares in 2006 877,507 877,310 Additional paid-in capital 105,516,211 104,740,178 Accumulated deficit (121,583,463) (119,805,328) -------------- -------------- Total stockholders' deficit (15,189,745) (14,187,840) -------------- -------------- Total liabilities and stockholders' deficit $ 18,086,168 $ 14,051,322 ============== ==============
UNIGENE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three months ended Nine months ended September 30, September 30, ------------------------- ------------------------- 2007 2006 2007 2006 ------------ ------------ ------------ ------------ Revenue: Product sales $ 4,142,635 $ 837,217 $11,258,044 $ 837,217 Royalties 1,628,476 672,771 4,548,575 1,218,417 Licensing revenue 280,691 189,189 859,237 567,567 Development fees -- -- 300,000 -- Grant and other revenue 291,668 1,693 424,098 20,547 ------------ ------------ ------------ ------------ 6,343,470 1,700,870 17,389,954 2,643,748 ------------ ------------ ------------ ------------ Operating expenses: Cost of goods sold 2,685,720 504,515 6,365,124 504,515 Research, development and facility expenses 1,911,673 1,923,230 6,214,768 5,382,361 General and administrative 1,706,563 1,468,774 5,685,886 4,553,033 ------------ ------------ ------------ ------------ 6,303,956 3,896,519 18,265,778 10,439,909 ------------ ------------ ------------ ------------ Operating income (loss) 39,514 (2,195,649) (875,824) (7,796,161) Other income (expense): Interest and other income 91,214 73,215 240,914 214,25 Interest expense- principally to stockholders (285,656) (392,400) (1,058,225) (1,177,377) ------------ ------------ ------------ ------------ Loss before income taxes (154,928) (2,514,834) (1,693,135) (8,759,287) Income tax expense (85,000) -- (85,000) -- ------------ ------------ ------------ ------------ Net loss $ (239,928) $(2,514,834) $(1,778,135) $(8,759,287) ============ ============ ============ ============ Loss per share - basic and diluted: Net loss per share $ (0.00) $ (0.03) $ (0.02) $ (0.10) ------------ ------------ ------------ ------------ Weighted average number of shares outstanding - basic and diluted 87,749,919 87,724,621 87,739,140 86,504,303 ============ ============ ============ ============
SOURCE: Unigene Laboratories, Inc.
The Investor Relations Group Investors: Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Lynn Granito, 212-825-3210
Unigene Announces Financial Results for the Third Quarter of 2007
6:00a ET November 12, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the three months and nine months ended September 30, 2007.
Revenue for the three months ended September 30, 2007 increased to $6,343,000 compared with $1,701,000 for the three months ended September 30, 2006. Revenue for the nine months ended September 30, 2007 increased to $17,390,000 compared with $2,644,000 for the nine months ended September 30, 2006. Revenue from Fortical sales and royalties was $5,771,000 and $13,607,000, respectively, for the three months and nine months ended September 30, 2007.
Fortical royalties were $1,628,000 and $673,000 for the three months ended September 30, 2007 and 2006, respectively, and $4,549,000 and $1,218,000 for the nine months ended September 30, 2007 and 2006, respectively. Fortical sales were $4,143,000 and $9,058,000 for the three months and nine months ended September 30, 2007, respectively. Fortical sales were $837,000 for the three months and nine months ended September 30, 2006. Sales of peptide to Novartis were $2,200,000 for the nine months ended September 30, 2007.
Net loss for the three months ended September 30, 2007 was $240,000, or $0.00 per share, compared with a net loss of $2,515,000, or $0.03 per share, for the three months ended September 30, 2006.
Net loss for the nine months ended September 30, 2007 was $1,778,000, or $0.02 per share, compared with a net loss of $8,759,000, or $0.10 per share, for the nine months ended September 30, 2006.
Operating expenses were $6,304,000 for the three months ended September 30, 2007, compared with $3,897,000 for the three months ended September 30, 2006 and were $18,266,000 for the nine months ended September 30, 2007, compared with $10,440,000 for the nine months ended September 30, 2006. The increases were primarily due to cost of goods sold resulting from the increased product sales to Upsher-Smith and Novartis. The three months ended September 30, 2007 and 2006 includes $84,000 and $134,000, respectively, in expenses for non-cash stock option compensation. The nine months ended September 30, 2007 and 2006 includes $766,000 and $561,000, respectively, in expenses for non-cash stock option compensation.
The Company's cash balance at September 30, 2007 was $7,004,000, an increase of approximately $3,647,000 from December 31, 2006. Accounts receivable at September 30, 2007 were $3,416,000, an increase of $2,176,000 from December 31, 2006.
Deferred licensing fees increased $4,641,000 from December 31, 2006, primarily due to the $5,500,000 Phase III milestone payment received from Novartis which was only partially recognized as revenue in the first nine months of 2007.
The Company believes that cash on hand, as well as cash generated from Fortical sales and royalties, will be sufficient to meet its obligations for the next twelve months.
Following are financial highlights:
-- Third quarter revenues increased 34% from second quarter
-- Third quarter Fortical sales and royalties increased 71% from second quarter
-- Fortical's market share improved to 49%
-- Positive operating income for third quarter
-- Positive cash flow from operations for nine months
"We are encouraged by the significant improvements in our financial performance," commented Dr. Warren Levy, President and CEO of Unigene. "With a stronger balance sheet and cash position, we intend to proceed with additional clinical studies for some of our peptides, as well as pre-clinical and clinical studies in our Site Directed Bone Growth Program."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
UNIGENE LABORATORIES, INC. CONDENSED BALANCE SHEETS September 30, December 31, 2007 2006 -------------- -------------- ASSETS (Unaudited) ---------------------------------------- Current assets: Cash and cash equivalents $ 7,004,197 $ 3,357,351 Accounts receivable 3,415,961 1,240,114 Inventory 2,676,225 5,283,000 Prepaid expenses and other current assets 226,530 303,444 -------------- -------------- Total current assets 13,322,913 10,183,909 Noncurrent inventory 445,958 -- Property, plant and equipment, net 2,419,560 2,364,141 Investment in joint venture 29,295 30,545 Patents and other intangibles, net 1,734,509 1,438,848 Other assets 133,933 33,879 -------------- -------------- Total assets $ 18,086,168 $ 14,051,322 ============== ============== LIABILITIES AND STOCKHOLDERS' DEFICIT ---------------------------------------- Current liabilities: Accounts payable $ 906,455 $ 884,958 Accrued expenses - other 2,093,011 1,806,707 Current portion - deferred licensing fees 1,262,756 762,752 Notes payable - stockholders -- 8,105,000 Accrued interest - stockholders -- 8,081,180 Current portion - capital lease obligations 49,029 70,780 Income tax payable 83,000 -- -------------- -------------- Total current liabilities 4,394,251 19,711,377 Notes payable-stockholders 15,737,517 -- Accrued interest-stockholders 473,218 -- Deferred licensing fees, excluding current portion 12,297,022 8,156,262 Capital lease obligations, excluding current portion 8,223 40,880 Deferred compensation 365,682 330,643 -------------- -------------- Total liabilities 33,275,913 28,239,162 -------------- -------------- Commitments and contingencies Stockholders' deficit: Common Stock - par value $.01 per share, authorized 135,000,000 shares, issued and outstanding: 87,750,715 shares in 2007 and 87,731,015 shares in 2006 877,507 877,310 Additional paid-in capital 105,516,211 104,740,178 Accumulated deficit (121,583,463) (119,805,328) -------------- -------------- Total stockholders' deficit (15,189,745) (14,187,840) -------------- -------------- Total liabilities and stockholders' deficit $ 18,086,168 $ 14,051,322 ============== ==============
UNIGENE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three months ended Nine months ended September 30, September 30, ------------------------- ------------------------- 2007 2006 2007 2006 ------------ ------------ ------------ ------------ Revenue: Product sales $ 4,142,635 $ 837,217 $11,258,044 $ 837,217 Royalties 1,628,476 672,771 4,548,575 1,218,417 Licensing revenue 280,691 189,189 859,237 567,567 Development fees -- -- 300,000 -- Grant and other revenue 291,668 1,693 424,098 20,547 ------------ ------------ ------------ ------------ 6,343,470 1,700,870 17,389,954 2,643,748 ------------ ------------ ------------ ------------ Operating expenses: Cost of goods sold 2,685,720 504,515 6,365,124 504,515 Research, development and facility expenses 1,911,673 1,923,230 6,214,768 5,382,361 General and administrative 1,706,563 1,468,774 5,685,886 4,553,033 ------------ ------------ ------------ ------------ 6,303,956 3,896,519 18,265,778 10,439,909 ------------ ------------ ------------ ------------ Operating income (loss) 39,514 (2,195,649) (875,824) (7,796,161) Other income (expense): Interest and other income 91,214 73,215 240,914 214,25 Interest expense- principally to stockholders (285,656) (392,400) (1,058,225) (1,177,377) ------------ ------------ ------------ ------------ Loss before income taxes (154,928) (2,514,834) (1,693,135) (8,759,287) Income tax expense (85,000) -- (85,000) -- ------------ ------------ ------------ ------------ Net loss $ (239,928) $(2,514,834) $(1,778,135) $(8,759,287) ============ ============ ============ ============ Loss per share - basic and diluted: Net loss per share $ (0.00) $ (0.03) $ (0.02) $ (0.10) ------------ ------------ ------------ ------------ Weighted average number of shares outstanding - basic and diluted 87,749,919 87,724,621 87,739,140 86,504,303 ============ ============ ============ ============
SOURCE: Unigene Laboratories, Inc.
The Investor Relations Group Investors: Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Lynn Granito, 212-825-3210
Unigene Announces Financial Results for the Third Quarter of 2007
6:00a ET November 12, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) reports its financial results for the three months and nine months ended September 30, 2007.
Revenue for the three months ended September 30, 2007 increased to $6,343,000 compared with $1,701,000 for the three months ended September 30, 2006. Revenue for the nine months ended September 30, 2007 increased to $17,390,000 compared with $2,644,000 for the nine months ended September 30, 2006. Revenue from Fortical sales and royalties was $5,771,000 and $13,607,000, respectively, for the three months and nine months ended September 30, 2007.
Fortical royalties were $1,628,000 and $673,000 for the three months ended September 30, 2007 and 2006, respectively, and $4,549,000 and $1,218,000 for the nine months ended September 30, 2007 and 2006, respectively. Fortical sales were $4,143,000 and $9,058,000 for the three months and nine months ended September 30, 2007, respectively. Fortical sales were $837,000 for the three months and nine months ended September 30, 2006. Sales of peptide to Novartis were $2,200,000 for the nine months ended September 30, 2007.
Net loss for the three months ended September 30, 2007 was $240,000, or $0.00 per share, compared with a net loss of $2,515,000, or $0.03 per share, for the three months ended September 30, 2006.
Net loss for the nine months ended September 30, 2007 was $1,778,000, or $0.02 per share, compared with a net loss of $8,759,000, or $0.10 per share, for the nine months ended September 30, 2006.
Operating expenses were $6,304,000 for the three months ended September 30, 2007, compared with $3,897,000 for the three months ended September 30, 2006 and were $18,266,000 for the nine months ended September 30, 2007, compared with $10,440,000 for the nine months ended September 30, 2006. The increases were primarily due to cost of goods sold resulting from the increased product sales to Upsher-Smith and Novartis. The three months ended September 30, 2007 and 2006 includes $84,000 and $134,000, respectively, in expenses for non-cash stock option compensation. The nine months ended September 30, 2007 and 2006 includes $766,000 and $561,000, respectively, in expenses for non-cash stock option compensation.
The Company's cash balance at September 30, 2007 was $7,004,000, an increase of approximately $3,647,000 from December 31, 2006. Accounts receivable at September 30, 2007 were $3,416,000, an increase of $2,176,000 from December 31, 2006.
Deferred licensing fees increased $4,641,000 from December 31, 2006, primarily due to the $5,500,000 Phase III milestone payment received from Novartis which was only partially recognized as revenue in the first nine months of 2007.
The Company believes that cash on hand, as well as cash generated from Fortical sales and royalties, will be sufficient to meet its obligations for the next twelve months.
Following are financial highlights:
-- Third quarter revenues increased 34% from second quarter
-- Third quarter Fortical sales and royalties increased 71% from second quarter
-- Fortical's market share improved to 49%
-- Positive operating income for third quarter
-- Positive cash flow from operations for nine months
"We are encouraged by the significant improvements in our financial performance," commented Dr. Warren Levy, President and CEO of Unigene. "With a stronger balance sheet and cash position, we intend to proceed with additional clinical studies for some of our peptides, as well as pre-clinical and clinical studies in our Site Directed Bone Growth Program."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
UNIGENE LABORATORIES, INC. CONDENSED BALANCE SHEETS September 30, December 31, 2007 2006 -------------- -------------- ASSETS (Unaudited) ---------------------------------------- Current assets: Cash and cash equivalents $ 7,004,197 $ 3,357,351 Accounts receivable 3,415,961 1,240,114 Inventory 2,676,225 5,283,000 Prepaid expenses and other current assets 226,530 303,444 -------------- -------------- Total current assets 13,322,913 10,183,909 Noncurrent inventory 445,958 -- Property, plant and equipment, net 2,419,560 2,364,141 Investment in joint venture 29,295 30,545 Patents and other intangibles, net 1,734,509 1,438,848 Other assets 133,933 33,879 -------------- -------------- Total assets $ 18,086,168 $ 14,051,322 ============== ============== LIABILITIES AND STOCKHOLDERS' DEFICIT ---------------------------------------- Current liabilities: Accounts payable $ 906,455 $ 884,958 Accrued expenses - other 2,093,011 1,806,707 Current portion - deferred licensing fees 1,262,756 762,752 Notes payable - stockholders -- 8,105,000 Accrued interest - stockholders -- 8,081,180 Current portion - capital lease obligations 49,029 70,780 Income tax payable 83,000 -- -------------- -------------- Total current liabilities 4,394,251 19,711,377 Notes payable-stockholders 15,737,517 -- Accrued interest-stockholders 473,218 -- Deferred licensing fees, excluding current portion 12,297,022 8,156,262 Capital lease obligations, excluding current portion 8,223 40,880 Deferred compensation 365,682 330,643 -------------- -------------- Total liabilities 33,275,913 28,239,162 -------------- -------------- Commitments and contingencies Stockholders' deficit: Common Stock - par value $.01 per share, authorized 135,000,000 shares, issued and outstanding: 87,750,715 shares in 2007 and 87,731,015 shares in 2006 877,507 877,310 Additional paid-in capital 105,516,211 104,740,178 Accumulated deficit (121,583,463) (119,805,328) -------------- -------------- Total stockholders' deficit (15,189,745) (14,187,840) -------------- -------------- Total liabilities and stockholders' deficit $ 18,086,168 $ 14,051,322 ============== ==============
UNIGENE LABORATORIES, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Three months ended Nine months ended September 30, September 30, ------------------------- ------------------------- 2007 2006 2007 2006 ------------ ------------ ------------ ------------ Revenue: Product sales $ 4,142,635 $ 837,217 $11,258,044 $ 837,217 Royalties 1,628,476 672,771 4,548,575 1,218,417 Licensing revenue 280,691 189,189 859,237 567,567 Development fees -- -- 300,000 -- Grant and other revenue 291,668 1,693 424,098 20,547 ------------ ------------ ------------ ------------ 6,343,470 1,700,870 17,389,954 2,643,748 ------------ ------------ ------------ ------------ Operating expenses: Cost of goods sold 2,685,720 504,515 6,365,124 504,515 Research, development and facility expenses 1,911,673 1,923,230 6,214,768 5,382,361 General and administrative 1,706,563 1,468,774 5,685,886 4,553,033 ------------ ------------ ------------ ------------ 6,303,956 3,896,519 18,265,778 10,439,909 ------------ ------------ ------------ ------------ Operating income (loss) 39,514 (2,195,649) (875,824) (7,796,161) Other income (expense): Interest and other income 91,214 73,215 240,914 214,25 Interest expense- principally to stockholders (285,656) (392,400) (1,058,225) (1,177,377) ------------ ------------ ------------ ------------ Loss before income taxes (154,928) (2,514,834) (1,693,135) (8,759,287) Income tax expense (85,000) -- (85,000) -- ------------ ------------ ------------ ------------ Net loss $ (239,928) $(2,514,834) $(1,778,135) $(8,759,287) ============ ============ ============ ============ Loss per share - basic and diluted: Net loss per share $ (0.00) $ (0.03) $ (0.02) $ (0.10) ------------ ------------ ------------ ------------ Weighted average number of shares outstanding - basic and diluted 87,749,919 87,724,621 87,739,140 86,504,303 ============ ============ ============ ============
SOURCE: Unigene Laboratories, Inc.
The Investor Relations Group Investors: Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Lynn Granito, 212-825-3210
NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas
Monday November 12, 7:00 am ET
Survival Superior to Standard Antibody Treatment In Rabies-infected Animals
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) said that in a confirmatory study, their nanoviricide™ drug candidates exhibited a consistent 20% to 30% survival in the test animals. In contrast, a commercial anti-rabies antibody produced 0% or no survival, as in the previous study. These results clearly demonstrate the superiority of the multi-valent targeting nanoviricides technology over antibody therapy. Scientists at the National Institute of Hygiene and Epidemiology in Hanoi, Vietnam performed the studies.
"Scientific data of this type provides further evidence of the effectiveness of these novel nanomedicines,” said Dr. Eugene Seymour, the Company's CEO. Consistent and reproducible repeat results have also been reported against common influenza (H1N1) using different production batches in animal studies previously performed by the Company.
“The fact that these repeat rabies studies were done in a premier independent government laboratory is extremely important to us,” said CEO Eugene Seymour, MD, adding, “this assures that no inherent bias influenced the outcome. This is of particular importance with any new technology on the cutting-edge of medical treatments. Our confirmatory strategy will be the same with the Ebola and Dengue work that is proceeding in two US government research laboratories.”
An estimated 10 million people receive post-exposure treatments each year after being exposed to rabies-suspect animals. About 30,000 people in the United States receive both pre-and post exposure prophylaxis every year, at a cost of over $1000 per treatment course. The annual number of deaths worldwide caused by rabies is estimated to be 55,000, mostly in rural areas of Africa and Asia, according to a recent World Health Organization report.
Rabies, a uniformly fatal disease found primarily in Africa and Southeast Asia, had never before been successfully treated with drugs.
There are currently no FDA-approved treatment options for rabies once symptoms develop. In addition, the Company believes that significantly increased survival rate of these lethally infected animals is possible in the dose-ranging studies to follow.
NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas
Monday November 12, 7:00 am ET
Survival Superior to Standard Antibody Treatment In Rabies-infected Animals
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) said that in a confirmatory study, their nanoviricide™ drug candidates exhibited a consistent 20% to 30% survival in the test animals. In contrast, a commercial anti-rabies antibody produced 0% or no survival, as in the previous study. These results clearly demonstrate the superiority of the multi-valent targeting nanoviricides technology over antibody therapy. Scientists at the National Institute of Hygiene and Epidemiology in Hanoi, Vietnam performed the studies.
"Scientific data of this type provides further evidence of the effectiveness of these novel nanomedicines,” said Dr. Eugene Seymour, the Company's CEO. Consistent and reproducible repeat results have also been reported against common influenza (H1N1) using different production batches in animal studies previously performed by the Company.
“The fact that these repeat rabies studies were done in a premier independent government laboratory is extremely important to us,” said CEO Eugene Seymour, MD, adding, “this assures that no inherent bias influenced the outcome. This is of particular importance with any new technology on the cutting-edge of medical treatments. Our confirmatory strategy will be the same with the Ebola and Dengue work that is proceeding in two US government research laboratories.”
An estimated 10 million people receive post-exposure treatments each year after being exposed to rabies-suspect animals. About 30,000 people in the United States receive both pre-and post exposure prophylaxis every year, at a cost of over $1000 per treatment course. The annual number of deaths worldwide caused by rabies is estimated to be 55,000, mostly in rural areas of Africa and Asia, according to a recent World Health Organization report.
Rabies, a uniformly fatal disease found primarily in Africa and Southeast Asia, had never before been successfully treated with drugs.
There are currently no FDA-approved treatment options for rabies once symptoms develop. In addition, the Company believes that significantly increased survival rate of these lethally infected animals is possible in the dose-ranging studies to follow.
This part is a joke,right?
efficiency of business management, while creating substantial shareholder value
Yep, one of the few-bless his soul.
OT: Remember our heros (no,not overpaid athletes) today:
http://www.flashdemo.net/gallery/wake/index.htm
Please remember them If They Die Today
http://www.flashdemo.net/gallery/wake/index.htm
Don't miss an opportunity to be scammed,lol. This is one of the few I have received since I began using spamcop.net.
You're half way there! Read on and Find out why we are so
Excited about NTCI!
NTCI is ready for a Major Break Out!
Company: NuTech Inc.
Current Price: $0.45
Target Price: $1.50
Notes: Strong Earnings Report Due
Nutech Inc. is an Up and Coming company in the High-Growth
Security sector. In today's environment there is no better
place to be. NTCI has enjoyed Extremely Strong sales Growth
and is expected to file a very Positive Profit report any day
now. We advise our readers to get in Before the
announcement hits the street.
Don't miss this rare Opportunity!
OT: Please remember our soldiers, present and past with this poem:
The embers glowed softly, and in their dim light,
I gazed round the room and I cherished the sight.
My wife was asleep, her head on my chest,
My daughter beside me, angelic in rest.
Outside the snow fell, a blanket of white,
Transforming the yard to a winter delight.
The sparkling lights in the tree I believe,
Completed the magic that was Christmas Eve.
My eyelids were heavy, my breathing was deep,
Secure and surrounded by love I would sleep.
In perfect contentment, or so it would seem,
So I slumbered, perhaps I started to dream.
The sound wasn't loud, and it wasn't too near,
But I opened my eyes when it tickled my ear.
Perhaps just a cough, I didn't quite know, Then the
sure sound of footsteps outside in the snow.
My soul gave a tremble, I struggled to hear,
And I crept to the door just to see who was near.
Standing out in the cold and the dark of the night,
A lone figure stood, his face weary and tight.
A soldier, I puzzled, some twenty years old,
Perhaps a Marine, huddled here in the cold.
Alone in the dark, he looked up and smiled,
Standing watch over me, and my wife and my child.
"What are you doing?" I asked without fear,
"Come in this moment, it's freezing out here!
Put down your pack, brush the snow from your sleeve,
You should be at home on a cold Christmas Eve!"
For barely a moment I saw his eyes shift,
Away from the cold and the snow blown in drifts..
To the window that danced with a warm fire's light
Then he sighed and he said "Its really all right,
I'm out here by choice. I'm here every night."
"It's my duty to stand at the front of the line,
That separates you from the darkest of times.
No one had to ask or beg or implore me,
I'm proud to stand here like my fathers before me.
My Gramps died at ' Pearl on a day in December,"
Then he sighed, "That's a Christmas 'Gram always remembers."
My dad stood his watch in the jungles of ' Nam ',
And now it is my turn and so, here I am.
I've not seen my own son in more than a while,
But my wife sends me pictures, he's sure got her smile.
Then he bent and he carefully pulled from his bag,
The red, white, and blue... an American flag.
I can live through the cold and the being alone,
Away from my family, my house and my home.
I can stand at my post through the rain and the sleet,
I can sleep in a foxhole with little to eat.
I can carry the weight of killing another,
Or lay down my life with my sister and brother..
Who stand at the front against any and all,
To ensure for all time that this flag will not fall."
"So go back inside," he said, "harbor no fright,
Your family is waiting and I'll be all right."
"But isn't there something I can do, at the least,
"Give you money," I asked, "or prepare you a feast?
It seems all too little for all that you've done,
For being away from your wife and your son."
Then his eye welled a tear that held no regret,
"Just tell us you love us, and never forget.
To fight for our rights back at home while we're gone,
To stand your own watch, no matter how long.
For when we come home, either standing or dead,
To know you remember we fought and we bled.
Is payment enough, and with that we will trust,
That we mattered to you as you mattered to us."
PLEASE, Would you do me the kind favor of sending this to as many
people as you can? Christmas will be coming soon and some credit is
due to our U.S. service
men and women for our being able to celebrate these festivities.
Let's try in this small way to pay a tiny bit of what we owe. Make
people stop and think
of our heroes, living and dead, who sacrificed themselves for us.
LCDR Jeff Giles, SC, USN
30th Naval Construction Regiment
OIC, Logistics Cell One
Al Taqqadum , Iraq.
Thieves of your dollars in congress:
Alaska Lawmakers Lose Political Clout
Aug 14 03:45 PM US/Eastern
By LARRY MARGASAK
Associated Press Writer
WASHINGTON (AP) - When he was a keeper of the federal purse strings, Sen. Ted Stevens of Alaska told another Republican senator who opposed the infamous "bridge to nowhere," "I don't threaten people. I promise people."
His home-state GOP colleague, Rep. Don Young, was not to be outdone. Last month he told a fellow House member who opposed education money for native Alaskans: "There is always another day when those who bite will be killed, too, and I am very good at that. Those that bite me will be bitten back."
Stevens and Young may not be promising, threatening or biting anymore, now that both are under federal investigation.
The investigations—and a questionable land deal that entangled the third member of Alaska's congressional delegation—also may have ended a modern-day gold rush that sent billions of federal dollars to the state.
Alaska's entire delegation is under an ethical cloud, something congressional historians say is unprecedented:
—Stevens is contending with an extraordinary FBI and IRS raid on his Girdwood, Alaska, home and a probe into his dealings with businessmen who oversaw remodeling of the house.
—Young is the subject of a federal investigation that includes his campaign finance practices, and he has been chided by the leaders of his own party for his threatening comments. He was left off a House- Senate conference on an annual water resources bill that he had handled as a committee chairman.
—Sen. Lisa Murkowski announced that she and her husband will sell back an undeveloped piece of riverfront property after a complaint to the Senate's ethics committee alleged the purchase was a sweetheart deal.
Stevens, 83, is the longest-serving Republican in Senate history—having taken office in 1968. Young, 74, has been in office since 1973. Both face election next year.
"They aren't as bulletproof as they once were," said Steve Ellis, vice president of Taxpayers for Common Sense, a group that tracks pet projects known as earmarks or pork-barrel spending. "The people are not going to be quite as afraid of taking on The Hulk or Don Young." "The Hulk" is a reference to Stevens, who occasionally sports a tie with the image of the Incredible Hulk cartoon character.
No other delegation has delivered like Alaska's, using a combination of intimidating tactics and powerful positions—especially when Republicans were in the majority through last year. Stevens headed the Senate Appropriations Committee. Young led the House Transportation Committee, making him the traffic cop for all road and mass transit projects.
More than 2,000 projects worth $7.5 billion have gone to Alaska since says Taxpayers for Common Sense. Alaska received a little over $1 billion in the 2005 highway bill.
A 2005-2007 study of earmarks by the group showed that Alaska—ranked 47th in population—has done far better than other states, when spending is calculated per person. Spending over the three-year period came to $4,311 per person in earmarked projects for Alaskans, while Hawaii was a distant second at $1,812. At the low end were the populous states of Texas, at $98 per person, and New York, $95 per person.
Part of the difference can be explained by Alaska's special needs, with its remote geography, rough terrain and extreme weather. But the clout of Stevens and Young also has played a huge role.
"There was a time when these were the gods in some ways, but it's a new world," said Bill Hoagland, a former Senate Appropriations Committee staff director under Stevens. "There are senators and congressmen who are new to the institution and don't have reason to be as scared as previous members. They don't have the same fear factor."
Still, Dr. Carl Shepro, a political science professor at the University of Alaska, said the investigations have not yet generated a public outcry against Stevens and Young in Alaska.
"They brought a lot of programs to the state. It will take a conviction to get large numbers of people against them," Shepro said.
"One of the things about Young that turns a lot of people off in D.C., and some people here, is the fact that he'll get in some people's faces." But most Alaskans appreciate that, he said. "A lot of voters think he's expressing individualism."
Federal authorities are scrutinizing Stevens' relationship with oil field services contractor Bill Allen, who helped oversee a renovation project that more than doubled the size of Stevens' Alaska home in Allen's company, VECO Inc., won tens of millions of dollars in federal contracts and officials were major political donors. Allen has pleaded guilty to bribing lawmakers in the state Legislature.
The Young probe, in part, involves his campaign finance practices, according to a law enforcement official who commented only on condition of anonymity. The investigation was first reported by The Wall Street Journal.
Former VECO CEO Allen held fundraisers called "the Pig Roast" for Young every August for 10 years.
Young's spokeswoman Meredith Kenny has declined to discuss the investigation.
Stevens says the interests of justice will be best served if he does not comment until after the investigation.
Murkowski says her land deal was "a judgment call that I made that allowed me and my husband to undergo a level of criticism that I believe is unfounded but has caused people to question me. I'm not willing to compromise that trust for any piece of property."
Murkowski had drawn criticism over her purchase—located along the scenic Kenai River southwest of Anchorage on the Kenai Peninsula—from a campaign contributor she called a lifelong family friend.
Hoagland, the former appropriations committee staff director under Stevens, said that even before the latest incidents, "the winds had already started to shift" away from Stevens and Young. It started, he said, with the defeat in late 2005 of the "bridge to nowhere"—a $223 million project connecting Alaska's lightly populated Gravina Island to Ketchikan. It was shelved after it drew scorn from the media and the public.
Then, both men were left in the minority by last November's election results.
Hoagland added, "The congressional environment on earmarks, the minority status, and on top of that the black cloud that hangs over ... particularly Stevens will lessen the amount of funding he and Young can channel back to state of Alaska."
"But he is a tough fighter. I never underestimate Ted Stevens."
Copyright 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
UGNE 10-Q better than expected:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24438096
UGNE 10Q better than expected:
http://www.unigene.com/investor_relations/sec_filings.html
Microfluidics To Unveil New M-110P Microfluidizer® Processor At AAPS 2007
11/7/2007
Microfluidics will unveil its newest portable M-110P Microfluidizer® processor, a bench top lab machine that requires no compressed air or cooling water, at the 2007 AAPS Annual Meeting and Exposition in San Diego, CA from November 12-14.
Utilizing Microfluidics’ fixed geometry diamond interaction chamber technology and ceramic plunger, the M-110P easily enables the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption with the fewest number of passes. Additionally, the M-110P allows flow rates between 110-155 ml/minute at any process pressure, which is a higher flow rate than any comparable, competitive product. This flow rate enables the efficient processing of pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P machine are guaranteed to be scaleable to pilot and/or production volumes.
The M-110P comes with a programmable logic controller (PLC) that manages on board operation including audio-visual alarms, alarm acknowledgment and silencing, and motor starter interlocks. In the event that an operating parameter is out of tolerance, this PC-based system will alert users to respond. The PLC also makes available 10 digital I/O connections, as well as an analog channel for added flexibility. Each processor can be customized depending on specific formulation parameters and is available with options for external controls, such as automated alarms and auto shutdown. Additionally, the M-110P offers options for the internal and external monitoring of several variables including temperature and pressure.
The M-110P can be fitted with optional communication modules that allow the operator to monitor and control the M-110P remotely as in a factory automation setting.
About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email mixinginfo@mfics.com or contact Microfluidics at 800.370.5452 for application information.
Source: Microfluidics
Forward This Article To An Associate
Basically 100% of their "PR's" have been bold faced lies. Do you consider those "forked tongues"?
So, after years of Vioxx harming and killing people, the govt. (FDA) tells Merck to pull it. Merck denies the harm (of course) then settles for a bargain. Blood sucking lawyers take 50% and the family of a poor dead Vioox user gets a paltry 100k.
Merck to Pay $4.85B Vioxx Settlement
Friday November 9, 11:56 am ET
By Linda A. Johnson, AP Business Writer
Merck Agrees to $4.85 Billion Settlement Over Pain Medication Vioxx
TRENTON, N.J. (AP) -- Merck & Co. said Friday it will pay $4.85 billion to end thousands of state and federal lawsuits over its painkiller Vioxx in one of the largest drug settlements ever.
Company officials estimated the deal, if accepted, would end 45,000 to 50,000 personal injury lawsuits involving U.S. Vioxx users who suffered a heart attack or ischemic stroke, the type in which blood flow to the brain is blocked.
ADVERTISEMENT
"Without this settlement, the litigation might very well stretch on for years," Merck executive vice president Kenneth Frazier said during a conference call.
He called the agreement "responsible and reasonable" and allows Merck to better quantify its liability, once estimated as high as $50 billion.
Negotiating teams met more than 50 times in eight states and spoke hundreds of times by telephone over many months to hammer out the deal, according to attorneys.
"I'm very happy with it," said Chris Seeger, one of the six plaintiff lawyers who helped negotiate the settlement. "It's a tremendous way to resolve this litigation."
Merck pulled Vioxx from the market Sept. 30, 2004 after its researchers determined the blockbuster arthritis treatment, then pulling in about $2.5 billion a year, doubled risk of heart attacks and strokes.
To qualify for a settlement, plaintiffs must have filed claims by Thursday and meet several criteria, including medical proof that they suffered a heart attack or stroke, that they received at least 30 Vioxx pills and that they received enough pills to support a presumption that they were ingested within two weeks before injury.
That is a big concession by Merck, which has long claimed that Vioxx caused harm only after 18 months of use. Those claims were dismissed by independent scientists and plaintiffs lawyers.
Merck stressed that the agreement is not a class action settlement and that it is not admitting fault.
Company executives and attorneys said as recently as last month that every case would be fought individually.
But on Friday, they said several factors made this "the right time" for the deal, including the expiration of the statute of limitations in 42 states.
Merck said it will take a pretax charge for the full $4.85 billion in the current quarter. It would not say whether insurance will cover any of that, but said much of the charge will be tax deductible.
Analyst Steve Brozak of WBB Securities called Merck's handling of the litigation "a Harvard casebook study of how to deal with a problematic product."
Investors seemed to agree, as Merck shares trading jumped nearly 5 percent, or $2.67, to $57.44 -- near their 52-week high of $58.36.
After losing its first case in a $253 million verdict that was later sharply reduced, Merck has won a string of civil cases. It has won 10 of 15 court verdicts to date. Some of those cases will be excluded from the settlement, but appeals in others continue.
The company said last month it had added $70 million to its reserves for defending lawsuits. As of Sept. 30, Merck had reserved a total of $1.92 billion for legal expenses and spent a total of $1.2 billion.
The deal becomes binding only if 85 percent of the plaintiffs in key categories agree to the deal: all pending heart attack and ischmic stroke cases, all cases involving deaths and all cases alleging more than 12 months of Vioxx use.
"I'm not in the least bit of doubt that we'll do it," said Russ Herman, a New Orleans attorney who served as chairman of the plaintiffs negotiating committee. "This was a really, really tough litigation for both sides; this way you have some certainty."
The deal was finalized in the early morning hours after attorneys for Merck and the plaintiffs met with three of the four judges overseeing nearly all Vioxx claims.
Seeger said the deal was put in motion last December when three key judges pushed the parties to open out-of-court talks.
"Every claimant is going to be compensated" once their claim is validated, he said.
Seeger said this deal is larger that the original settlement in cross-state rival Wyeth's diet drug litigation, which was $3.75 billion initially but ballooned past $20 billion with repeated revisions.
Merck lawyers said they had closely scrutinized that and other cases to find ways to ensure that its settlement does not exceed the $4.85 billion, of which $4 billion will go to heart attack claimants and the rest to stroke claimants.
Among other things, potential claimants will have to have prior medical documentation of a heart attack or stroke, and they will not be able to later opt out of the settlement. Also, all law firms involved in the "steering committees" directing pretrial discovery and other coordination of both state and federal cases must get every one of their clients to settle.
Payments would vary, depending on severity of injuries, length of time that Vioxx was used and each person's risk factors for cardiovascular disease. A complex system would assign points to each claimant. Payments could start as early as August 2008.
Lawyers fees are to come out of the $4.85 billion fund, based on the percentage in their contingency agreements with clients; additional fees will go to the law firms that together amassed more than 50 million pages of documents for use by all plaintiffs' lawyers.
Attorneys for both sides presented the deal Friday morning to U.S. District Judge Eldon E. Fallon in New Orleans.
A total of about 60,000 personal injury cases have been filed, including thousands on hold under agreements suspending the statute of limitations, plus about 265 potential class action cases, some of which allege shareholder losses.
The deal does not include people in foreign countries, any with different injuries, any with stock-related claims or a group with no evident injuries that is suing for Merck to pay for medical monitoring.
Settlement documents: http://www.officialvioxxsettlement.com/
Biocryst reports Q3 results:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24388282
BioCryst Reports Third Quarter 2007 Financial Results and Corporate Update
7:00a ET November 8, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the third quarter ended September 30, 2007.
Key Operating Results
The Company reported revenues of $20.5 million in the third quarter of 2007, compared to $1.8 million in the third quarter of 2006. The net loss for the quarter ended September 30, 2007 was $11.0 million, or $0.32 per share, compared to a net loss of $15.6 million, or $0.53 per share, for the quarter ended September 30, 2006.
As of September 30, 2007, the Company had cash, cash equivalents and investments of $102.2 million.
Third Quarter 2007 Financial Results
Collaborative and other research and development revenues increased in the third quarter of 2007 to $20.5 million compared to $1.8 million in the same period last year. The increase is primarily due to revenue recognized from the contract with the U.S. Department of Health and Human Services (DHHS) for the development of peramivir and the continuing amortization of deferred revenue from our collaborative agreements.
Research and development ("R&D") expenses were $29.7 million in the third quarter of 2007, compared to $16.7 million in the third quarter of 2006. The increase in R&D expenses is primarily attributable to an increase in clinical trial related expenses, manufacturing costs for our lead drug candidates and costs related to an increase in the personnel supporting the advanced development of our drug candidates.
General and administrative ("G&A") expenses were $2.6 million for third quarter of 2007, compared to $1.6 million for the third quarter of 2006. The increase in G&A expenses is primarily due to an increase in personnel related costs as a result of increased headcount, including an increase in the non- cash share-based compensation expense for the quarter and an increase in professional fees.
Year-to-Date 2007 Financial Results
Collaborative and other research and development revenues increased for the nine months ended September 30, 2007 to $43.1 million compared to $4.1 million in the same period of last year. The year-to-date increase is primarily due to revenue recognized from the contract with DHHS for the development of peramivir and the continuing amortization of deferred revenue from our collaborative agreements.
R&D expenses were $64.9 million for the nine months ended September 30, 2007, compared to $35.9 million for the same period in 2006. The increase in R&D expenses is primarily attributable to an increase in clinical trial related expenses, manufacturing costs for our lead drug candidates and costs related to an increase in the personnel supporting the advanced development of our drug candidates.
G&A expenses were $7.0 million for the nine months ended September 30, 2007, compared to $4.5 million for the same period in 2006. The increase in G&A expenses is primarily due to personnel related costs, including an increase of $1.2 million in the non-cash share-based compensation expense for the period, and an increase in professional fees.
The net loss for the nine months ended September 30, 2007 was $26.8 million, or $0.86 per share, compared to a net loss of $33.6 million, or $1.15 per share for the same period last year.
Recent corporate and financial highlights -- Continued development of intramuscular (i.m.) peramivir clinical trial In September, BioCryst reported preliminary results from a phase II study of the intramuscular formulation of peramivir. The study was designed to determine if this formulation of peramivir could reduce the duration of symptoms in subjects with acute influenza. While the results of the trial indicate that a single dose of peramivir demonstrated a treatment effect over placebo, the improvement was not statistically significant. The Company continues to receive and analyze data from this recently completed trial. In addition, the Company is carrying out additional PK studies to support this analysis. Armed with the further analysis and following discussion with the FDA, the Company is planning to initiate the pivotal program in time to take advantage of the upcoming influenza season. -- Continued development of intravenous (i.v.) peramivir Phase II clinical trial In July, BioCryst initiated a Phase II clinical trial of i.v. peramivir for the treatment of hospitalized subjects with severe influenza. The trial is designed to compare the efficacy and safety of i.v. peramivir to orally administered oseltamivir in subjects who require hospitalization due to acute influenza. BioCryst plans to continue the trial in the northern hemisphere during the 2007/2008 influenza season. -- Initiation of oral forodesine HCl pivotal clinical trial In October, BioCryst enrolled the first patient in a pivotal Phase II clinical trial of oral forodesine HCl in patients with cutaneous T- cell lymphoma (CTCL). The multinational trial is being conducted in accordance with a Special Protocol Assessment (SPA) agreement between the FDA and BioCryst granted earlier this year. -- Initiation of oral BCX-4208 Phase IIa clinical trial In July, BioCryst and Roche initiated the first Phase II clinical trial to evaluate BCX-4208. The study, led by Roche is designed to evaluate the compound in patients with moderate to severe plaque psoriasis. -- Completion of $65.3 million financing In August, BioCryst completed a $65.3 million private placement financing with a group of existing BioCryst stock holders. The offering was composed of approximately 8.3 million shares of BCRX common stock, as well as warrants to purchase an additional approximately 3.2 million shares.
"During the third quarter, we continued to lay the groundwork needed to bring our products to market," said Jon P. Stonehouse, President and CEO of BioCryst. "We made progress with our peramivir, forodesine HCl and BCX-4208 clinical programs and gained added financial flexibility through the completion of a private placement to a group of existing BCRX stock holders."
Conference Call and Webcast
At 10:00 a.m. Eastern Time today, BioCryst will host a conference call and live webcast. BioCryst management will discuss the company's third quarter results and provide an update on the company's programs and business results.
To access the webcast via the internet, log on to http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternately, please call 1-800-860-2442 (U.S.) or 1-412-858-4600 (international). Telephone replay will be available. To access the replay, please call 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and dial the participant passcode 413134#. The webcast will be archived on http://www.biocryst.com
FAIRFIELD, N.J.--(BUSINESS WIRE)--November 07, 2007
Unigene Laboratories, Inc. (OTCBB: UGNE, www.unigene.com) will
release financial results for the third quarter ended September 30,
2007, before the market opens on Monday, November 12th. The Company
will also host a conference call that morning, at 9:00 AM EST, to
discuss its third quarter financial results and to provide a Company
update.
Unigene invites all those interested in hearing management's
discussion to join the call by dialing 866-585-6398 for participants
in the United States and 416-849-9626 for international participants.
A replay will be available for seven days after the call and can be
accessed by dialing 866-245-6755 for participants in the United States
and 416-915-1035 for international participants. When prompted, enter
passcode #596692. The conference call may also be accessed via the Web
at www.unigene.com; a link will be provided for listeners to join the
call.
I did not call DTC but sent complaint to Interpol not only to investigate shares being unconverted but to look into the entire circus of clowns at NWOL.
My TDA account did show converted shares this morning.